ADMS Adamas Pharmaceuticals, Inc.

15.52
-0.28  -2%
Previous Close 15.80
Open 15.80
Price To book 2.95
Market Cap 347.01M
Shares 22,359,000
Volume 108,493
Short Ratio 29.44
Av. Daily Volume 135,695

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17832695
  2. 8-K - Current report 17832684
  3. 8-K - Current report 17826335
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826311
  5. 8-K - Current report 17790419

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
PDUFA date August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia

Latest News

  1. Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
  2. Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
  3. [$$] Adamas Receives $100 Million Royalty-Backed Financing From HealthCare Royalty Partners
  4. Edited Transcript of ADMS earnings conference call or presentation 9-May-17 8:30pm GMT
  5. Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
  6. Adamas reports 1Q loss
  7. Adamas Reports Recent Achievements and First Quarter 2017 Financial Results
  8. Investor Network: Adamas Pharmaceuticals, Inc. to Host Earnings Call
  9. Adamas Reports Inducement Grant to New Chief Operating Officer
  10. Adamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : May 5, 2017
  11. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : May 4, 2017
  12. Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
  13. Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102
  14. Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease
  15. Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting
  16. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : April 5, 2017
  17. Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
  18. Adamas to Present at the 16th Annual Needham Healthcare Conference
  19. Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  20. Are These 2 Biotechs Diamonds in the Rough?